Angle (AGL)


AGL Share PerformanceMore

52 week high76.85 05/10/16
52 week low44.00 30/03/17
52 week change -14.00 (-21.88%)
4 week volume1,978,221 27/04/17

Media for (AGL)

Presenter: Andrew Newland, Chief Executive

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Business Update

RNS Number: 9768D Angle PLC 03 May 2017 For immediate release 3 May 2017 ANGLE plc ("the Company") BUSINESS UPDATE HIGHLIGHTS PROGRESS WITH PARSORTIX LIQUID BIOPSY Ovarian cancer clinical studies progressing well with patient enrolment completed. Headline data on target for reporting this quarter MD Anderson Cancer Center signed...

Holding(s) in Company

RNS Number: 4527B Angle PLC 04 April 2017 For immediate release 4 April 2017 ANGLE plc ("the Company") Holding(s) in Company The Company has been informed by Lombard Odier Investment Managers group ("Lombard") that, following its recent acquisition of Henderson Volantis from Henderson Global plc ("Henderson"), Lombard has acquired ordina...

Parsortix enables analysis in head and neck cancer

RNS Number: 2731B Angle PLC 03 April 2017 For immediate release 3 April 2017 ANGLE plc ("the Company") PARSORTIX ENABLES GENE EXPRESSION ANALYSIS IN HEAD AND NECK CANCER Customer presents clinically relevant results at AACR 2017 with Parsortix where alternative approaches have failed University of Athens, Attikon University H...

Prostate Cancer Update

RNS Number: 9546A Angle PLC 30 March 2017 For immediate release 30 March 2017 ANGLE plc ("the Company") POTENTIAL FOR PREDICTION OF METASTASIS IN PROSTATE CANCER Barts Cancer Institute present new findings at World CDx Europe 2017 conference in London ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is...

Selected for European Cancer ID Programme

RNS Number: 6697W Angle PLC 13 February 2017 For immediate release 13 February 2017 ANGLE plc ("the Company") PARSORTIX SELECTED FOR EUROPEAN CANCER-ID PROGRAMME ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that it has been formally selected for CANCER-ID, the European con...

Interim Evaluation of Ovarian Cancer Study

RNS Number: 1486V Angle PLC 26 January 2017 For immediate release 26 January 2017 ANGLE plc ("the Company") POSITIVE INTERIM EVALUATION OF OVARIAN CANCER CLINICAL STUDIES Patient enrolment European study now over 90% complete and US study 70% complete Headline data from the full studies expected in Q2, 2017 ANGLE plc (A...

Interim Results

RNS Number: 1504V Angle PLC 26 January 2017 For Immediate Release 26 January 2017 ANGLE plc ("ANGLE" or "the Company") Interim Results for the six months ended 31 October 2016 OVARIAN CANCER CLINICAL STUDIES PROGRESSING WELL ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces its unau...

ANGLE Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017

Andrew Newland the Chief Executive of ANGLE Plc (AGL) [LSE:AGL] the specialist medtech company, is to present at th...

Fundamental DataMore

Dividend yield0 %

Equity Research (AGL)

InnovaDerma* (IDP.L) 133.5p £15.81m The UK developer of life sciences, beauty and personal care products today provided an update on trading and announces it has secured new e-tailer distribution...
Europa Oil & Gas Hldgs(EOG.L) 5.87p £14.39m The UK and Ireland focussed exploration, development and production company, has signed a Farm-Out Agreement with a wholly owned subsidiary of leading...
edison investment research
Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid...

Latest discussion posts More

  • Re: Could our little machine

    Agree nice - I think that it is known that Parsortix can indicate whether the drugs are working or the dose may be altered to suit the patient. However, the BBC (I haven't ...
  • Could our little machine

    have helped? Get the impression it wasn't with whats been said on the radio - may be wrong on this. With budgets under ...
  • Re: Q2 2017 trigger?

    Fair point.
    claude reins

Users' HoldingsMore

Users who hold Angle also hold..

Codes & Symbols